Medicine
fromArs Technica
2 days agoClinical trial shows gene editing works for -Thalassaemia, too
An improved gene editing system reactivates a fetal hemoglobin gene to treat β-Thalassaemia, building on CRISPR's success with sickle-cell anemia.
"I'm on the cusp of immortality," he says. Every six weeks, he pops into the clinic for a full body reboot that typically includes a nervous system reset and hyperbaric oxygen therapy.